[(pyridine-3-carbonyl)-amino]-acetic acid methyl ester | 57397-47-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(pyridine-3-carbonyl)-amino]-acetic acid methyl ester
• 英文别名: 3-(N-(methoxycarbonylmethyl)-carboxamido)-pyridine；nicotinyl-glycine-methyl ester；methyl nicotinoylglycinate；N-nicotinoyl-glycine methyl ester；N-Nicotinoyl-glycin-methylester；N-Methoxycarbonylmethyl-nicotinamide；Glycine, N-(3-pyridinylcarbonyl)-, methyl ester；methyl 2-(pyridine-3-carbonylamino)acetate
• CAS: 57397-47-4
• 化学式: C₉H₁₀N₂O₃
• mdl: MFCD01213569
• 分子量: 194.19
• InChiKey: YZFCSHLOLUYQKO-UHFFFAOYSA-N

物化性质

• 沸点：
  415.6±25.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)
• 保留指数：
  1634

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(pyridine-3-carbonyl)-amino]-acetic acid methyl ester 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以58%的产率得到5-methoxy-2-(3-pyridyl)thiazole
  参考文献：
  名称：

  A new series of fluorescent 5-methoxy-2-pyridylthiazoles with a pH-sensitive dual-emission

  摘要：

  合成了一系列新的荧光团，5-美氧基-2-(2、3或4-吡啶基)噻唑（分别为2-MPT、3-MPT和4-MPT），并研究了它们的光物理性质。2-MPT和4-MPT在极性溶剂中具有高度荧光特性。结合理论计算，对不同溶剂中激发态寿命的研究表明，它们的荧光主要源自内部电荷转移激发态。通过静态和瞬态荧光光谱研究了它们基态和激发态的酸碱性质。2-MPT和4-MPT在水相系统中表现出pH敏感的荧光行为，在pH值2至6的范围内具有双重发射。

  DOI：

  10.1039/b604910a
• 作为产物：
  描述：

  烟酸 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 [(pyridine-3-carbonyl)-amino]-acetic acid methyl ester
  参考文献：
  名称：

  Synthesis, biological activity screening and molecular modeling study of acylaminoacetamide derivatives

  摘要：

  In this study, non-rigid analogs of thalidomide have been designed in order to develop potentially active, more effective and safer lead molecules for disorders caused or contributed by inflammation. Five different series of acylaminoacetamide compounds were synthesized, and the biological inhibitory potency of the title compounds has been determined by evaluating their effects on COX-2 isoenzyme expression and PGE(2) production in A549 (human lung adenocarcinoma) cell lines. Among the studied series, N-[2-(isopropylamino)-2-oxoethyl]isonicotinamide is the most active inhibitory compound on COX-2 isoenzyme expression, and N-[2-oxo-2-(pyrolydine-1-yl)etyl]isonicotinamide is the most active inhibitory compound on the biosynthesis of PGE(2). Molecular docking studies and molecular dynamics simulations were also applied to investigate non-covalent interactions of the most active compounds inside the active side of the crystal structure of murine cyclooxygenase 2 (mCOX-2) isoenzyme.

  DOI：

  10.1007/s00044-015-1419-4

文献信息

• Homogeneous catalytic aminocarbonylation of nitrogen-containing iodo-heteroaromatics. Synthesis of N-substituted nicotinamide related compounds
  作者：Attila Takács、Balázs Jakab、Andrea Petz、László Kollár

  DOI：10.1016/j.tet.2007.07.017

  日期：2007.10

  Various primary and secondary amines, including amino acid methyl esters, were used as nucleophiles in palladium-catalysed aminocarbonylation of 2-iodopyridine, 3-iodopyridine and iodopyrazine. N-Substituted nicotinamides and 3-pyridyl-glyoxylamides (2-oxo-carboxamide type derivatives) of potential biological importance can be obtained from 3-iodopyridine as a result of simple and double carbon monoxide

  各种伯胺和仲胺，包括氨基酸甲酯，在钯催化的2-碘吡啶，3-碘吡啶和碘吡嗪的氨基羰基化反应中用作亲核试剂。具有潜在生物学重要性的N-取代的烟酰胺和3-吡啶基-乙二酰乙酰胺（2-氧代-羧酰胺型衍生物）可以分别通过简单和两次一氧化碳插入而从3-碘吡啶获得。后面的例子可以通过使用升高的一氧化碳压力以合成上可接受的产率获得。相反，仅通过使用2-碘吡啶和碘吡嗪在整个压力范围内获得N-烷基/芳基-甲酰胺。
• Spectroscopic investigation of H atom transfer in a gas-phase dissociation reaction: McLafferty rearrangement of model gas-phase peptide ions
  作者：Michael J. Van Stipdonk、Dale R. Kerstetter、Christopher M. Leavitt、Gary S. Groenewold、Jeffrey Steill、Jos Oomens

  DOI：10.1039/b802314j

  日期：——

  study isotopically-labeled ions generated by McLafferty rearrangement of nicotinyl-glycine-tert-butyl ester and betaine-glycine-tert-butyl ester. The tert-butyl esters were incubated in a mixture of D(2)O and CH(3)OD to induce solution-phase hydrogen-deuterium exchange and then converted to gas-phase ions using electrospray ionization. McLafferty rearrangement was used to generate the free-acid forms of

  使用波长选择性红外多光子光解离（WS-IRMPD）研究了烟酰胺基-甘氨酸-叔丁酯和甜菜碱-甘氨酸-叔丁酯的McLafferty重排产生的同位素标记离子。将叔丁酯在D（2）O和CH（3）OD的混合物中孵育，以诱导溶液相氢-氘交换，然后使用电喷雾电离将其转化为气相离子。McLafferty重排用于通过转移H原子和消除丁烯生成相应模型肽的游离酸形式。具体目的是使用WS-IRMPD产生的振动光谱来确定H原子是否保留在酸基上，或迁移到一个或多个其他可交换位点。IRMPD结果在120​​0-1900 cm（-1）范围内与不同同位素标记的异构体的理论光谱之间的比较清楚地表明，H原子位于C端酸基团上，而迁移到酰胺位置上的迁移量可忽略不计。实验的时间尺度。这项研究的结果表明，使用McLafferty重排技术制备肽酯可能是一种有效的原位生成H原子同位素示踪剂的方法，用于随后的肽片段研究中分子内质子迁移的研究。
• Oxazole and thiazole derivatives and their use for treating disorders
  申请人：H. Lundbeck A/S

  公开号：US04925858A1

  公开（公告）日：1990-05-15

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 -R.sup.5 are as defined in the specification; as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式子的新化合物，其中点线表示可选键：##STR1## 其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1-R.sup.5如规范中所定义；以及其个别立体异构体和药学上可接受的酸加成盐。此外，本发明还涉及制备式I化合物的方法、新的中间体、包含其的药物组合物以及通过给予式I化合物的非毒性有效量治疗因乙酰胆碱（AcCh）或肌动系统功能障碍而引起的疾病的方法。
• 1,2,3-Triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck A/S

  公开号：US04866077A1

  公开（公告）日：1989-09-12

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms, R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及下列公式的新化合物，其中点线表示可选键：##STR1## 其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫选取的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1选自氢、低碳基，可选地取代苯基，该苯基可以被卤素、低碳基或低烷氧基取代，或者是一个R.sup.6-CO-NH-CH.sub.2-或R.sup.6-O-CO-基团，其中R.sup.6是低碳基，支链或直链，或者是可选地被卤素、三氟甲基、低碳基、羟基、低烷氧基或低酰氧基取代的苯基；R.sup.2和R.sup.3相同或不同，每个代表氢、低碳基、环戊烷基（3-6个碳原子）、低烯基、低二烯基、低炔基，可选地被羟基、卤素或苯基取代，其中苯基可以被卤素、三氟甲基、低碳基、羟基或低烷氧基取代；R.sup.2和R.sup.3还可以分别选自三氟甲基或可选地被卤素、三氟甲基、低碳基、羟基、低烷氧基或低酰氧基取代的苯基，或者R.sup.2和R.sup.3分别是OR.sup.7或SR.sup.7基团，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包含2个或更多个碳原子，则R.sup.4和R.sup.5相同或不同，每个定义为R.sup.2或R.sup.3，如果“het”只包含一个碳原子，则杂环上只有一个取代基R.sup.4，且R.sup.4定义为R.sup.2或R.sup.3，以及其个别立体异构体和药学上可接受的酸加合物。此外，本发明还涉及制备公式I化合物的方法、新的中间体、含有该化合物的制药组合物以及通过给予公式I化合物的非毒性有效量来治疗由乙酰胆碱（AcCh）或肌动系统功能紊乱引起的疾病的方法。
• 1,2,3-triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck, A/S

  公开号：USRE036374E1

  公开（公告）日：1999-11-02

  The present invention relates to novel compounds of the following formula, where the dotted line designates in optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,4- or 1,3,4-oxadiazole, R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifuoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula 1, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式的新化合物，其中点线表示可选键：##STR1##其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，前提是“het”不能表示1,4-或1,3,4-噁二唑，R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可以取代为卤素、较低的烷基或较低的烷氧基，或者是一个R.sup.6 -CO-NH-CH.sub.2-或R.sup.6-O-CO-基团，其中R.sup.6是较低的烷基，分支或非分支，或苯环，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基；R.sup.2和R.sup.3相同或不同，每个表示氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，在其中苯基可以取代为卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基；R.sup.2和R.sup.3可以进一步分别选择三氟甲基或苯基，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基，或R.sup.2和R.sup.3可以分别是OR.sup.7或SR.sup.7基团，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或多个碳原子，则R.sup.4和R.sup.5相同或不同，每个定义为R.sup.2或R.sup.3，如果“het”仅包括一个碳原子，则杂环环上只有一个取代基R.sup.4，定义为R.sup.2或R.sup.3，以及其个别立体异构体和药学上可接受的酸加合物。此外，本发明还涉及制备公式1化合物的方法、新的中间体、含有同样化合物的制药组合物以及通过给予公式I化合物的非毒性有效量治疗由乙酰胆碱（AcCh）或肌动系统功能不良引起的疾病的方法。

表征谱图